AbbVie (ABBV) Q2 2026 Earnings Call Transcript
AbbVie (NYSE:ABBV) reported Q2 2026 revenue of nearly $17B, up 10.2%, and adjusted EPS of $3.65, above the guidance midpoint. Full-year revenue guidance was raised to about $67.6B and adjusted EPS to $13.87-$14.07. Growth was led by SKYRIZI and RINVOQ, while HUMIRA and IMBRUVICA declined amid biosimilar and IRA pricing pressure.
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised full-year revenue guidance, the adjusted EPS range incorporating acquisition dilution, and quantified product-level headwinds (HUMIRA biosimilars, IMBRUVICA IRA pricing). Regulatory and clinical updates (QLIPTA approvals, SKYRIZI Crohn’s endoscopic response, ABBV-1.76 penetration) add upside optionality but are less directly tied to near-term numbers than guidance.
Market read
Guidance raise with quantified acquisition dilution and explicit product-level drags provides a clear basis for near-term estimate revisions and positioning.
What to watch
The transcript emphasizes operational growth and market share, but traders may need to scrutinize assumptions behind peak sales targets, acquisition integration timing, and leverage trajectory post-Apogee close.
Background
This is an AbbVie Q2 2026 earnings call transcript covering segment performance, product sales trends, and 2026 guidance, including the Apogee Therapeutics acquisition.
Ticker impact
AbbVie reported Q2 results and raised full-year revenue guidance to about $67.6B, with adjusted EPS guidance $13.87 to $14.07.
Moderately positive bias for ABBV as raised revenue and EPS outlook offset known drags from HUMIRA biosimilar and IMBRUVICA IRA pricing.
The article provides specific, decision-relevant guidance numbers (revenue and EPS ranges) and quantifies acquisition dilution and key product headwinds, which can drive estimate revisions and positioning.
Market effects
Biopharma read-through on immunology and oncology pricing pressure (IRA) versus growth resilience in newer franchises.
European regulatory milestones (QLIPTA approvals) support incremental demand expectations for migraine therapies.
Global market share claims for SKYRIZI and pipeline penetration metrics may influence broader sentiment toward large-cap pharma growth durability.
Counterpoint
The guidance raise may be partially offset by ongoing structural pressures: HUMIRA biosimilar decline and IMBRUVICA IRA pricing drag remain large.
Key entities
- companyAbbVie Inc.
Reported Q2 2026 performance and raised full-year revenue and adjusted EPS guidance; discussed Apogee acquisition dilution and leverage targets.
- companyApogee Therapeutics
Acquisition referenced as contributing about $0.14 of dilution to 2026 adjusted EPS outlook.
- productSKYRIZI
Reported Q2 sales of $5.5B and raised full-year revenue guidance to $21.7B.
- productHUMIRA
Reported Q2 sales of $706M, down 36.1% operationally due to biosimilar competition.
- productIMBRUVICA
Reported Q2 sales down 29.4% operationally, attributed to IRA pricing and competitive share pressure.
